Browsing by Subject "cost-effectiveness"
Now showing 1 - 6 of 6
Results Per Page
Sort Options
Item Open Access Cost-Effectiveness of Amphotericin B Deoxycholate Versus Itraconazole for Induction Therapy of Talaromycosis in Human Immunodeficiency Virus-Infected Adults in Vietnam.(Open forum infectious diseases, 2021-07-05) Buchanan, James; Altunkaya, James; Van Kinh, Nguyen; Van Vinh Chau, Nguyen; Trieu Ly, Vo; Thi Thanh Thuy, Pham; Hai Vinh, Vu; Thi Hong Hanh, Doan; Thuy Hang, Nguyen; Phuong Thuy, Tran; van Doorn, Rogier; Thwaites, Guy; Gray, Alastair; Le, ThuyBackground
Talaromycosis (penicilliosis) is an invasive fungal infection and a major cause of human immunodeficiency virus (HIV)-related deaths in Southeast Asia. Guidelines recommend induction therapy with amphotericin B deoxycholate; however, treatment with itraconazole has fewer toxic effects, is easier to administer, and is less expensive. Our recent randomized controlled trial in Vietnam found that amphotericin B was superior to itraconazole with respect to 6-month mortality. We undertook an economic evaluation alongside this trial to determine whether the more effective treatment is cost-effective.Methods
Resource use, direct and indirect costs, and health and quality-of-life outcomes (measured using quality-adjusted life-years [QALYs]) were evaluated for 405 trial participants from 2012 to 2016. Both a Vietnamese health service and a broader societal costing perspective were considered. Mean costs and QALYs were combined to calculate the within-trial cost-effectiveness of amphotericin vs itraconazole from both perspectives.Results
From a Vietnamese health service perspective, amphotericin increases costs but improves health outcomes compared to itraconazole, at a cost of $3013/QALY gained. The probability that amphotericin is cost-effective at a conventional (World Health Organization CHOICE) threshold of value for money is 46%. From a societal perspective, amphotericin is cost-reducing and improves outcomes compared to itraconazole, and is likely to be a cost-effective strategy at any value for money threshold greater than $0.Conclusions
Our analysis indicates that induction therapy with amphotericin is a cost-effective treatment strategy for HIV-infected adults diagnosed with talaromycosis in Vietnam. These results provide the evidence base for health care providers and policy makers to improve access to and use of amphotericin.Item Open Access Cost-effectiveness of posterior lumbar interbody fusion and/or transforaminal lumbar interbody fusion for grade 1 lumbar spondylolisthesis: a 5-year Quality Outcomes Database study.(Journal of neurosurgery. Spine, 2024-08) Yee, Timothy J; Liles, Campbell; Johnson, Sarah E; Ambati, Vardhaan S; DiGiorgio, Anthony M; Alan, Nima; Coric, Domagoj; Potts, Eric A; Bisson, Erica F; Knightly, John J; Fu, Kai-Ming G; Foley, Kevin T; Shaffrey, Mark E; Bydon, Mohamad; Chou, Dean; Chan, Andrew K; Meyer, Scott; Asher, Anthony L; Shaffrey, Christopher I; Slotkin, Jonathan R; Wang, Michael Y; Haid, Regis W; Glassman, Steven D; Virk, Michael S; Mummaneni, Praveen V; Park, PaulObjective
Posterior lumbar interbody fusion (PLIF) and/or transforaminal lumbar interbody fusion (TLIF), referred to as "PLIF/TLIF," is a commonly performed operation for lumbar spondylolisthesis. Its long-term cost-effectiveness has not been well described. The aim of this study was to determine the 5-year cost-effectiveness of PLIF/TLIF for grade 1 degenerative lumbar spondylolisthesis using prospective data collected from the multicenter Quality Outcomes Database (QOD).Methods
Patients enrolled in the prospective, multicenter QOD grade 1 lumbar spondylolisthesis module were included if they underwent single-stage PLIF/TLIF. EQ-5D scores at baseline, 3 months, 12 months, 24 months, 36 months, and 60 months were used to calculate gains in quality-adjusted life years (QALYs) associated with surgery relative to preoperative baseline. Healthcare-related costs associated with the index surgery and related reoperations were calculated using Medicare reimbursement-based cost estimates and validated using price transparency diagnosis-related group (DRG) charges and Medicare charge-to-cost ratios (CCRs). Cost per QALY gained over 60 months postoperatively was assessed.Results
Across 12 surgical centers, 385 patients were identified. The mean patient age was 60.2 (95% CI 59.1-61.3) years, and 38% of patients were male. The reoperation rate was 5.7%. DRG 460 cost estimates were stable between our Medicare reimbursement-based models and the CCR-based model, validating the focus on Medicare reimbursement. Across the entire cohort, the mean QALY gain at 60 months postoperatively was 1.07 (95% CI 0.97-1.18), and the mean cost of PLIF/TLIF was $31,634. PLIF/TLIF was associated with a mean 60-month cost per QALY gained of $29,511. Among patients who did not undergo reoperation (n = 363), the mean 60-month QALY gain was 1.10 (95% CI 0.99-1.20), and cost per QALY gained was $27,591. Among those who underwent reoperation (n = 22), the mean 60-month QALY gain was 0.68 (95% CI 0.21-1.15), and the cost per QALY gained was $80,580.Conclusions
PLIF/TLIF for degenerative grade 1 lumbar spondylolisthesis was associated with a mean 60-month cost per QALY gained of $29,511 with Medicare fees. This is far below the well-established societal willingness-to-pay threshold of $100,000, suggesting long-term cost-effectiveness. PLIF/TLIF remains cost-effective for patients who undergo reoperation.Item Open Access Evaluating the Cost-Effectiveness of Domestic Policy Portfolios for Emissions Abatement in the Electricity Sector(2009-04-24T17:07:29Z) Wanner, BrentIncreased scientific certainty about anthropogenic climate change coupled with the Obama administration taking office has the United States poised to enact legislation to reduce greenhouse gas emissions. Studies have suggested that a combination of policy instruments will be more economically efficient than any single strategy in order to correct for multiple externalities in the market. This paper employs a theoretical model of the electricity sector developed in Fischer & Newell (2008) to compare the cost-effectiveness of individual and combinations of policy instruments. Despite many of the parameter values changing significantly in the numerical application of the model, this analysis affirms the relative rankings of the policy instruments in terms of economic efficiency found in Fischer & Newell (2008). Beginning with the most cost-effective instrument, the order is as follows: emissions price, tradable emissions performance standard, tax on fossil output, renewables portfolio standard, renewables production subsidy, and R&D subsidy. Several policy portfolios are modeled and costs compared to an emissions price. The results indicate that simultaneous policies for climate mitigation tend to be more cost-effective than any single instrument. While combining an emissions price with a renewables portfolio standard offers cost advantages over an emissions price alone, the best complementary policy for an emissions price is an R&D subsidy. The sensitivity analyses show that this is a robust conclusion for a broad range of parameter values. It is therefore recommended that policymakers seriously consider a substantial R&D subsidy for renewable energy technologies in addition to establishing a cap-and-trade system.Item Open Access Influenza Vaccination Implementation in Sri Lanka: A Cost-Effectiveness Analysis.(Vaccines, 2023-05) Neighbors, Coralei E; Myers, Evan R; Weerasinghe, Nayani P; Wijayaratne, Gaya B; Bodinayake, Champica K; Nagahawatte, Ajith; Tillekeratne, L Gayani; Woods, Christopher WInfluenza causes an estimated 3 to 5 million cases of severe illness annually, along with substantial morbidity and mortality, particularly in low- and middle-income countries (LMICs). Currently, Sri Lanka has no influenza vaccination policies and does not offer vaccination within the public healthcare sector. Therefore, we performed a cost-effectiveness analysis of influenza vaccine implementation for the Sri Lankan population. We designed a static Markov model that followed a population cohort of Sri Lankans in three age groups, 0-4, 5-64, and 65+ years, through two potential scenarios: trivalent inactivated vaccination (TIV) and no TIV across twelve-monthly cycles using a governmental perspective at the national level. We also performed probabilistic and one-way sensitivity analyses to identify influential variables and account for uncertainty. The vaccination model arm reduced influenza outcomes by 20,710 cases, 438 hospitalizations, and 20 deaths compared to no vaccination in one year. Universal vaccination became cost-effective at approximately 98.01% of Sri Lanka's 2022 GDP per capita (incremental cost-effectiveness ratio = 874,890.55 Rs/DALY averted; 3624.84 USD/DALY averted). Results were most sensitive to the vaccine coverage in the 5-64-year-old age group, the cost of the influenza vaccine dose in the 5-64-years-old age group, vaccine effectiveness in the under-5-years-old age group, and the vaccine coverage in the under-5-years-old age group. No value for a variable within our estimated ranges resulted in ICERs above Rs. 1,300,000 (USD 5386.15) per DALY adverted. Providing influenza vaccines was considered highly cost-effective compared to no vaccines. However, large-scale national studies with improved data are needed to better inform estimates and determine the impact of vaccination implementation.Item Open Access Quantifying the utility of taking pills for preventing adverse health outcomes: a cross-sectional survey.(BMJ Open, 2015-05-11) Hutchins, Robert; Pignone, Michael P; Sheridan, Stacey L; Viera, Anthony JOBJECTIVES: The utility value attributed to taking pills for prevention can have a major effect on the cost-effectiveness of interventions, but few published studies have systematically quantified this value. We sought to quantify the utility value of taking pills used for prevention of cardiovascular disease (CVD). DESIGN: Cross-sectional survey. SETTING: Central North Carolina. PARTICIPANTS: 708 healthcare employees aged 18 years and older. PRIMARY AND SECONDARY OUTCOMES: Utility values for taking 1 pill/day, assessed using time trade-off, modified standard gamble and willingness-to-pay methods. RESULTS: Mean age of respondents was 43 years (19-74). The majority of the respondents were female (83%) and Caucasian (80%). Most (80%) took at least 2 pills/day. Mean utility values for taking 1 pill/day using the time trade-off method were: 0.9972 (95% CI 0.9962 to 0.9980). Values derived from the standard gamble and willingness-to-pay methods were 0.9967 (0.9954 to 0.9979) and 0.9989 (95% CI 0.9986 to 0.9991), respectively. Utility values varied little across characteristics such as age, sex, race, education level or number of pills taken per day. CONCLUSIONS: The utility value of taking pills daily in order to prevent an adverse CVD health outcome is approximately 0.997.Item Open Access The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets.(Open forum infectious diseases, 2018-01) Morgan, Jake R; Kim, Arthur Y; Naggie, Susanna; Linas, Benjamin PBackground
Direct acting antiviral hepatitis C virus (HCV) therapies are highly effective but costly. Wider adoption of an 8-week ledipasvir/sofosbuvir treatment regimen could result in significant savings, but may be less efficacious compared with a 12-week regimen. We evaluated outcomes under a constrained budget and cost-effectiveness of 8 vs 12 weeks of therapy in treatment-naïve, noncirrhotic, genotype 1 HCV-infected black and nonblack individuals and considered scenarios of IL28B and NS5A resistance testing to determine treatment duration in sensitivity analyses.Methods
We developed a decision tree to use in conjunction with Monte Carlo simulation to investigate the cost-effectiveness of recommended treatment durations and the population health effect of these strategies given a constrained budget. Outcomes included the total number of individuals treated and attaining sustained virologic response (SVR) given a constrained budget and incremental cost-effectiveness ratios.Results
We found that treating eligible (treatment-naïve, noncirrhotic, HCV-RNA <6 million copies) individuals with 8 weeks rather than 12 weeks of therapy was cost-effective and allowed for 50% more individuals to attain SVR given a constrained budget among both black and nonblack individuals, and our results suggested that NS5A resistance testing is cost-effective.Conclusions
Eight-week therapy provides good value, and wider adoption of shorter treatment could allow more individuals to attain SVR on the population level given a constrained budget. This analysis provides an evidence base to justify movement of the 8-week regimen to the preferred regimen list for appropriate patients in the HCV treatment guidelines and suggests expanding that recommendation to black patients in settings where cost and relapse trade-offs are considered.